Stock News•4 days ago
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos (GKOS) stock surged 67% year to date, driven by iDose TR momentum and the Epioxa launch, which lifted 2026 guidance and expanded its ophthalmology platform.
MarketLens
Glaukos' Insider Sales: Diversification, Not Distress, Amidst Strong Growth
1 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•5 days ago
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares
An Elanco director raised their stake by 10,000 shares, increasing direct equity holdings by 10%, signaling insider confidence in the company's outlook.
Stock News•1 week ago
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
An insider sold nearly 53,000 shares of a consumer health stock for ~$900,000 at $16.78 per share, liquidating 54% of their direct stake after a 23% 12-month gain.
Stock News•1 months ago
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Glaukos CFO Alex Thurman sold 10,000 shares for ~$1.6M at $155/share on July 9, representing 19% of his total equity holdings.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•48 minutes ago
Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026
Stock News•49 minutes ago
Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?
Stock News•1 hour ago
Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know
Stock News•1 hour ago
Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.
Stock News•1 hour ago